Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

被引：20
|
作者：
Nathwani, Nitya [1 ]
Krishnan, Amrita Y. [1 ]
Huang, Qin [2 ]
Kim, Young [2 ]
Karanes, Chatchada [1 ]
Smith, Eileen P. [1 ]
Forman, Stephen J. [1 ]
Sievers, Eric [3 ]
Thomas, Sandra H. [1 ]
Chen, Robert W. [1 ]
机构：
[1] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA
[3] Seattle Genet, Bothell, WA USA
来源：
LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 10期
关键词：
STEM-CELL TRANSPLANTATION; DISEASE; TUBULIN; TRIAL;
D O I：
10.3109/10428194.2012.666543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2051 / 2053
页数：3
相关论文
共 50 条
  • [31] Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression
    Chen, Wen
    Zhang, Zhihong
    ONCOTARGETS AND THERAPY, 2025, 18 : 1 - 14
  • [32] Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
    Scott, Lesley J.
    DRUGS, 2017, 77 (04) : 435 - 445
  • [33] Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
    Lesley J. Scott
    Drugs, 2017, 77 : 435 - 445
  • [34] Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    Duvic, Madeleine
    Tetzlaff, Michael
    Clos, Audra L.
    Gangar, Pamela
    Talpur, Rakhshandra
    BLOOD, 2012, 120 (21)
  • [35] Brentuximab Vedotin (SGN-35) in a 3-Year-Old Child With Relapsed Systemic Anaplastic Large Cell Lymphoma
    Mikles, Bethany
    Levine, Jennifer
    Gindin, Tatyana
    Bhagat, Govind
    Satwani, Prakash
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2014, 36 (02) : E85 - E87
  • [36] Chemorefractory Hodgkin's lymphoma in a young patient - rapid and complete remission with brentuximab vedotin (SGN 35)
    Schwitter, M.
    Mey, U.
    Kienle, D.
    von Moos, R.
    Cathomas, R.
    ONKOLOGIE, 2011, 34 : 70 - 70
  • [37] Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding
    Al-Rohil, Rami N.
    Torres-Cabala, Carlos A.
    Patel, Anisha
    Tetzlaff, Michael T.
    Ivan, Doina
    Nagarajan, Priyadharsini
    Curry, Jonathan L.
    Miranda, Roberto N.
    Duvic, Madeleine
    Prieto, Victor G.
    Aung, Phyu P.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (12) : 1161 - 1166
  • [38] Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma
    Elias, Alexandra
    Marques-Piubelli, Mario L.
    Nair, Ranjit
    Prakash, Rishab
    Ahmed, Sairah
    Malpica, Luis
    Lee, Hun Ju
    Xu, Jie
    Flowers, Christopher R.
    Neelapu, Sattva S.
    Vega, Francisco
    Miranda, Roberto
    Iyer, Swami P.
    BLOOD, 2023, 142
  • [39] Selection For Brentuximab Vedotin Resistant Lymphoma Cell Lines Leads To Downregulation Of Surface CD30 Expression
    Chen, Robert
    Hou, Jessie
    Reddy, Megan
    Newman, Edward
    Forman, Stephen J.
    Kane, Susan
    BLOOD, 2013, 122 (21)
  • [40] Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update
    Advani, Ranjana H.
    Shustov, Andrei R.
    Brice, Pauline
    Bartlett, Nancy L.
    Rosenblatt, Joseph D.
    Illidge, Tim
    Matous, Jeffrey
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Connors, Joseph M.
    Yang, Yin
    Kennedy, Dana A.
    Pro, Barbara
    BLOOD, 2011, 118 (21) : 204 - 204
12345